

## Practical Insights in Novel Immune Therapies in Multiple Myeloma

WEDNESDAY, NOVEMBER 16, 2022 | VIRTUAL

6:00-6:05 PM	<b>Welcome</b> Noopur Raje
6:05-6:20 PM	Overview of immune therapies and CAR T cells: Defining the unmet need in relapsed refractory multiple myeloma; MOA of CAR T cells and TCEs and clinical data Nikhil Munshi
6:20-6:35 PM	Patients and the process – defining patient selection for TCEs/CAR T cell therapy in practice - Understanding of CAR T eligibility to ensure the right patient is referred for CAR T therapy Amrita Krishnan
6:35-6:45 PM	<b>Case study with discussion</b> Moderator: Amrita Krishnan Presenter: Murali Janakiram
6:45-7:00 PM	Managing TCE/CAR T cell toxicities: Practical tips for short and long-term adverse events associated with CAR T cell therapy (focus on needs for coordination between community centers and CAR T centers) Krina Patel
7:00-7:15 PM	Managing relapse following novel immune therapies and Future advances Tom Martin
7:15-7:25 PM	<b>Case study with discussion</b> Moderator: Tom Martin Presenter: Vanessa Kennedy
7:25-7:30 PM	Wrap-Up

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:





Supported by a grant from Pfizer Inc.

